Literature DB >> 2472586

Silicone oil for the treatment of severe proliferative diabetic retinopathy.

N D Brourman1, M S Blumenkranz, M S Cox, M T Trese.   

Abstract

Although silicone oil is being used with increasing frequency for proliferative vitreoretinopathy (PVR), few studies have reported on its use for severe forms of proliferative diabetic retinopathy (PDR). Vitreous microsurgery with silicone oil tamponade was performed on 34 patients (37 eyes) with refractory severe neovascular glaucoma and/or recurrent retinal detachment (RD) from PDR that failed to respond to conventional techniques including vitrectomy, membrane peeling, gas tamponade and photocoagulation. With all patients followed a minimum of 6 months (mean, 13 months), anatomic attachment was maintained in 26 (70%) of the eyes. At the last follow-up examination, a final visual acuity of at least 5/200 was found in 9 (24%) of 37 eyes and 9 (35%) of 26 anatomically successful cases. Regression of iris neovascularization occurred in 8 (36%) of 22 eyes with rubeosis and the silicone oil was removed in 3 (8%) eyes. Significant complications included band keratopathy in nine (24%) eyes, corneal decompensation in three (8%) eyes, and recurrent retinal detachment in seven (19%) eyes.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2472586     DOI: 10.1016/s0161-6420(89)32828-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  16 in total

1.  Retinal redetachment after removal of intraocular silicone oil tamponade.

Authors:  J B Jonas; H L Knorr; R M Rank; W M Budde
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

2.  Vitrectomy with silicone oil infusion in severe diabetic retinopathy.

Authors:  A Castellarin; R Grigorian; N Bhagat; L Del Priore; M A Zarbin
Journal:  Br J Ophthalmol       Date:  2003-03       Impact factor: 4.638

3.  Silicone oil in diabetic vitrectomy.

Authors:  D McLeod
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

4.  The outcomes of pars plana vitrectomy without endotamponade for tractional retinal detachment secondary to proliferative diabetic retinopathy.

Authors:  Rao Muhammad Rashad Qamar; Muhammad Imran Saleem; Muhammad Farhan Saleem
Journal:  Int J Ophthalmol       Date:  2013-10-18       Impact factor: 1.779

5.  Temporary silicone oil tamponade in the treatment of complicated diabetic retinal detachments.

Authors:  M Gonvers
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

6.  Safety and feasibility of a novel intravitreal tamponade using a silicone oil/acetyl-salicylic acid suspension for proliferative vitreoretinopathy: first results of the Austrian Clinical Multicenter Study.

Authors:  Martina Theresa Kralinger; Ulrike Stolba; Michaela Velikay; Stefan Egger; Susanne Binder; Andreas Wedrich; Anton Haas; Jean-Marie Parel; Gerhard Franz Kieselbach
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-04-28       Impact factor: 3.117

7.  Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid.

Authors:  R H Y Asaria; C H Kon; C Bunce; C S Sethi; G A Limb; P T Khaw; G W Aylward; D G Charteris
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

8.  Clinical variables and their relation to visual outcome after vitrectomy in eyes with diabetic retinal traction detachment.

Authors:  Ellen C La Heij; Sadettin Tecim; Alfons G H Kessels; Albert T A Liem; Wouter J Japing; Fred Hendrikse
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-12-09       Impact factor: 3.117

9.  The Outcomes of Pars Plana Vitrectomy without Tamponade for Tractional Retinal Detachment Secondary to Diabetic Retinopathy.

Authors:  Rao Muhammad Rashad Qamar; Muhammad Imran Saleem; Muhammad Farhan Saleem
Journal:  Malays J Med Sci       Date:  2013-05

Review 10.  Heavy and standard silicone oil: intraocular inflammation.

Authors:  Andrea Russo; Francesco Morescalchi; Simone Donati; Elena Gambicorti; Claudio Azzolini; Ciro Costagliola; Francesco Semeraro
Journal:  Int Ophthalmol       Date:  2017-03-13       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.